Latest announcement takeaways

1. Sozinibercept is a first-in-class VEGF-C/D 'trap' inhibitor designed to be used in combination with standard anti-VEGF-A therapies to improve visual outcomes in wet AMD patients.

2. In Phase 2b trials, sozinibercept demonstrated superiority in visual acuity gains when combined with ranibizumab compared to ranibizumab alone, particularly in patients with occult and minimally classic lesions.

3. Two Phase 3 trials (COAST and ShORe) are ongoing, with topline data expected in early Q2 2025 and mid-2025 respectively.

4. The company aims to address a significant unmet need, as many patients on current anti-VEGF-A therapies still experience vision loss long-term.

5. Sozinibercept has shown a favorable safety profile comparable to standard of care in completed trials.

6. The potential market for sozinibercept is substantial, estimated at ~$15 billion globally.

7. Opthea has secured funding through a Development Funding Agreement and recent financings, with a cash runway expected to last through both pivotal trial readouts.

8. The company is preparing for potential commercialization, including manufacturing scale-up and regulatory preparations.

9. Sozinibercept has patent protection through 2034, with potential for extension beyond that date.

Overall, Opthea positions sozinibercept as a potentially disruptive therapy in the wet AMD market, offering improved visual outcomes when combined with existing treatments.

Very curious to hear your thoughts about this!